Rad51 supports triple negative breast cancer metastasis. - Wikidata - wikimedia - TriplyDB

Rad51 supports triple negative breast cancer metastasis.

Rad51 supports triple negative breast cancer metastasis.

http://www.wikidata.org/entity/Q33917622

about

DNA repair targeted therapy: The past or future of cancer treatment?MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer.Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.Suppression of cell migration by phospholipase C-related catalytically inactive protein-dependent modulation of PI3K signalling Activation of homologous recombination DNA repair in human skin fibroblasts continuously exposed to X-ray radiation Association between a functional variant in RAD51 gene's 3' untranslated region and its mRNA expression in lymphoblastoid cell lines.Holliday junction trap shows how cells use recombination and a junction-guardian role of RecQ helicase.RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.Role of NRP-1 in VEGF-VEGFR2-Independent Tumorigenesis.A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.Rosiglitazone enhances radiosensitivity by inhibiting repair of DNA damage in cervical cancer cells.Estrogen induces RAD51C expression and localization to sites of DNA damage Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.Comprehensive molecular biomarker identification in breast cancer brain metastases.Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis.

P2860

Q26768679-5B77106E-4806-4F71-8B48-C2A3B440449F Q28829013-CA383D11-E8CB-45F5-93E8-3DC8B97596AD Q33733042-FFE3EE16-6C56-4482-8963-48C5601428F4 Q33865098-DD93669A-C2A1-4893-91FD-49ABCCF01DDC Q33905794-FBA25822-BDB0-4234-84DD-B15960D059EB Q36413634-3BD7D8D9-287D-43C2-8AE9-5D2D458988FC Q37297871-52F6F00F-3BFE-418C-91C2-11FA9C946D60 Q37574376-0C5C9C4B-4DAB-490A-B7B5-EB4D15751123 Q37644990-04140189-444B-4FFF-9D4B-045F906E7F20 Q38750618-4F4FDAB4-32FC-4BDC-A261-F966CAD3BFD7 Q38872621-C54307D1-5269-442A-9E01-BDA1BD606CE9 Q38873958-6729992C-93F3-4914-8067-9628F5F13E50 Q42345398-A7430914-97CB-4FB3-84BC-A8B8F39ECFB7 Q42496885-D9571DC2-8CDF-47BF-93E7-118247485367 Q47098306-7F975571-C1F5-48F5-BBDE-72EE042E1B61 Q48588785-71B59D51-1D70-4C4F-A8CF-0414B3DCAC92 Q52362244-66A57884-9FDC-4B1C-ADE7-B308D534D9EA

P2860

Rad51 supports triple negative breast cancer metastasis.

http://www.wikidata.org/entity/Q33917622

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Rad51 supports triple negative breast cancer metastasis.

@ast

Rad51 supports triple negative breast cancer metastasis.

@en

type

label

Rad51 supports triple negative breast cancer metastasis.

@ast

Rad51 supports triple negative breast cancer metastasis.

@en

prefLabel

Rad51 supports triple negative breast cancer metastasis.

@ast

Rad51 supports triple negative breast cancer metastasis.

@en

P1433

Q33917622-BA5AC7FF-ECC8-4070-91D7-33F09E1BA988

P1476

Q33917622-82D09573-5107-43DF-AD3E-5B984111533D

P2093

Q33917622-10D6B25A-E0F9-4ED2-A1CA-33FA82DD12E7

Q33917622-210189D9-1B7E-4670-9A89-734C9E371A0D

Q33917622-4B66C076-63B3-4FED-91EC-0F6D261E6B4D

Q33917622-69D55769-2C06-41DA-B025-65C19032E0A4

Q33917622-76F3022E-AEC8-4B87-8892-1EBA81DE697D

Q33917622-8AFB279A-FD6C-4D38-9FF7-A3760D59FD39

Q33917622-AB4EC969-A71D-42E2-AE44-1CB956DDE9CD

Q33917622-E5D077CD-024E-4943-8F17-1F6B8B401392

P2860

Q33917622-01D07472-4551-47A1-84FC-CBAF662134A0

Q33917622-07C2E7B6-7B2E-4F4B-99F4-3D6167A9331D

Q33917622-0EA3B3B0-EF2C-4B55-A2D6-318DFE1902E9

Q33917622-13AE6787-FC6B-4C76-A465-80EA80608390

Q33917622-16B2F4D1-68CA-458E-8057-5A46F205EC15

Q33917622-1C017238-D376-4EDA-903E-97330C5B6D72

Q33917622-1FD09DA9-FB70-4DA4-8E45-21CCB0034B66

Q33917622-24848D8F-748C-464D-BCF2-1A6C0252FC6C

Q33917622-2A7DF119-540E-4959-8558-15430F7B1745

Q33917622-2DC79512-A330-4FF3-8A90-91DD671A5C52

P304

Q33917622-0453E5D9-9C2C-4ED1-84E4-05C204B10742

P31

Q33917622-A2030D66-35C6-476C-8CBB-3B8EBD38CD3B

P356

Q33917622-944EF4ED-4CAB-4AB1-B9BD-90E0696675BB

P407

Q33917622-98FF45F2-9D7B-4AA1-B886-5F85A970D3AF

P433

Q33917622-2E7878C9-7E96-44ED-A252-1D31D919B1BE

P478

Q33917622-D02235AC-BDF9-48D6-8C9D-BA1C854E73AF

P50

Q33917622-28BC882C-387C-4AB3-9211-FE312D1C6B53

Q33917622-71E17AB0-F6F9-490A-8947-F6D60A76306E

Q33917622-9B6CE89E-C332-4675-8B83-CEFE21C3D64C

Q33917622-A1B5A1C3-58EF-4610-AC5A-E65BDEC07086

P577

Q33917622-32EB4A11-103C-4045-83EC-1F695EE8C3A5

P5875

Q33917622-53D565AE-38AF-476A-B285-CAA71294875C

P698

Q33917622-CFFE14E5-45D7-425F-995C-7AE4971C7C8C

P932

Q33917622-BBD4362A-393A-4B0E-8DBF-0E3587A200ED

P356

ONCOTARGET.1923

P1433

P1476

Rad51 supports triple negative breast cancer metastasis.

@en

P2093

Adrian P Wiegmans

http://www.w3.org/2001/XMLSchema#string

Julia J Gorski

http://www.w3.org/2001/XMLSchema#string

Kum Kum Khanna

http://www.w3.org/2001/XMLSchema#string

Leonard Da Silva

http://www.w3.org/2001/XMLSchema#string

Nicole Chee

http://www.w3.org/2001/XMLSchema#string

Pei-Yi Yap

http://www.w3.org/2001/XMLSchema#string

Peter T Simpson

http://www.w3.org/2001/XMLSchema#string

Robin Anderson

http://www.w3.org/2001/XMLSchema#string

P2860

Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer

High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

The consequences of Rad51 overexpression for normal and tumor cells

Overexpression of RAD51 occurs in aggressive prostatic cancer

Linkage of early-onset familial breast cancer to chromosome 17q21

RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib

High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome

Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer

Genes that mediate breast cancer metastasis to lung

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

P304

3261-3272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.1923

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Georgia Chenevix-Trench

Sunil R Lakhani

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262191474

http://www.w3.org/2001/XMLSchema#string

P698

24811120

http://www.w3.org/2001/XMLSchema#string

P932

4102808

http://www.w3.org/2001/XMLSchema#string